Robert Lechleider net worth and biography

Robert Lechleider Biography and Net Worth

Insider of Immunome

Prior to joining Immunome, Dr. Lechleider was the Chief Medical Officer at OncoResponse, where he oversaw the development of the company’s proprietary oncology pipeline. Before OncoResponse, Dr. Lechleider served as the Senior Vice President of clinical development for Seagen, where he was responsible for directing the development of the early and late-stage portfolios, including the successful initial licensing of Padcev® for the treatment of previously treated metastatic urothelial cancer.

Dr. Lechleider began his biotech career at MedImmune (an Astra Zeneca company) and went on to positions of increasing responsibility at Human Genome Sciences and Macrogenics before heading development at Seagen. Prior to his career in biotech, Dr. Lechleider held academic positions where he studied basic cellular and molecular biology.

Dr. Lechleider earned his A.B. from Princeton University and his M.D. from the University of Illinois College of Medicine at Chicago before receiving his clinical residency in internal medicine at Beth Israel-Deaconess Medical Center in Boston, and later in medical oncology at the National Cancer Institute (NCI) in Bethesda.

What is Robert Lechleider's net worth?: The estimated net worth of Robert Lechleider is at least $125,017.55 as of November 21st, 2024. Lechleider owns 15,805 shares of Immunome stock worth more than $125,018 as of May 13th. This net worth evaluation does not reflect any other investments that Lechleider may own. Additionally, Lechleider receives an annual salary of $512,490.00 as Insider at Immunome. Learn More about Robert Lechleider's net worth.
How old is Robert Lechleider?: Lechleider is currently 63 years old. There are 1 older executives and no younger executives at Immunome. Learn More on Robert Lechleider's age.
What is Robert Lechleider's salary?: As the Insider of Immunome, Inc., Lechleider earns $512,490.00 per year. There are 2 executives that earn more than Lechleider. The highest earning executive at Immunome is Dr. Clay B. Siegall Ph.D., President, CEO & Chairman, who commands a salary of $1,430,000.00 per year. Learn More on Robert Lechleider's salary.
How do I contact Robert Lechleider?: The corporate mailing address for Lechleider and other Immunome executives is , , . Immunome can also be reached via phone at 610-321-3700 and via email at investors@immunome.com. Learn More on Robert Lechleider's contact information.
Has Robert Lechleider been buying or selling shares of Immunome?: Robert Lechleider has not been actively trading shares of Immunome in the last ninety days. Most recently, on Thursday, November 21st, Robert Lechleider bought 15,805 shares of Immunome stock. The stock was acquired at an average cost of $9.48 per share, with a total value of $149,831.40. Following the completion of the transaction, the insider now directly owns 15,805 shares of the company's stock, valued at $149,831.40. Learn More on Robert Lechleider's trading history.
Who are Immunome's active insiders?: Immunome's insider roster includes Jean Bienaime (Director), Jack Higgins (Insider), Robert Lechleider (Insider), Michael Lefenfeld (Director), Michael Rapp (Director), Max Rosett (CFO), Purnanand Sarma (CEO), Clay Siegall (CEO), Philip Tsai (CTO), and Bruce Turner (Insider). Learn More on Immunome's active insiders.
Are insiders buying or selling shares of Immunome?: In the last twelve months, Immunome insiders bought shares 9 times. They purchased a total of 418,262 shares worth more than $3,425,760.18. In the last twelve months, insiders at the sold shares 2 times. They sold a total of 17,904 shares worth more than $279,313.12. The most recent insider tranaction occured on March, 26th when CEO Clay B Siegall bought 137,100 shares worth more than $999,459.00. Insiders at Immunome own 8.6% of the company. Learn More about insider trades at Immunome.
Information on this page was last updated on 3/26/2025.

Robert Lechleider Insider Trading History at Immunome

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/21/2024	Buy	15,805	$9.48	$149,831.40	15,805

Robert Lechleider Buying and Selling Activity at Immunome

Immunome Company Overview

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Today's Range

Now: $7.91

$7.84

$8.37

50 Day Range

MA: $7.71

$5.56

$9.34

2 Week Range

Now: $7.91

$5.15

$16.81

Volume

1,771,365 shs

Average Volume

918,628 shs

Market Capitalization

$688.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Robert Lechleider Biography and Net Worth

What is Robert Lechleider's net worth?

How old is Robert Lechleider?

What is Robert Lechleider's salary?

How do I contact Robert Lechleider?

Has Robert Lechleider been buying or selling shares of Immunome?

Who are Immunome's active insiders?

Are insiders buying or selling shares of Immunome?